Multiple System Atrophy (MSA)
Conditions
Interventions
True Stimulation Group in MSA-P:Active transcranial magnetic stimulation treatment
Placebo Stimulation Group in MSA-P:Sham transcranial magnetic stimulation treatment
True Stimulation Group in MSA-C:Active transcranial magnetic stimulation treatment
Placebo Stimulation Group in MSA-C:Sham transcranial magnetic stimulation treatment
Sponsors
The Third Xiangya Hospital of Central South University
Eligibility
Sex/Gender
All
Age
30 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Clinical diagnosis of either "clinically confirmed MSA" or "probable MSA" based on the 2022 diagnostic criteria. 2. Genetic testing has excluded polyQ diseases. 3. Age between 30 and 75 years (inclusive). 4. Willingness to participate in this study and provision of informed consent.
Exclusion criteria
Exclusion criteria: 1. Presence of neurological diseases such as epilepsy, intracranial trauma, severe stroke, intracranial infection, or autoimmune encephalitis, or potential factors that may induce epilepsy (e.g., metabolic abnormalities such as hyponatremia, hypocalcemia, hypomagnesemia, hypoglycemia, hyperglycemia, renal failure/uremia, hepatic failure, or thyroid dysfunction). 2. Patients with movement disorders caused by other identifiable lesions on brain imaging, or those with movement disorders secondary to cerebrovascular disease, alcohol, or drug-induced cerebellar abnormalities, or movement disorders caused by motor paresis or musculoskeletal diseases. 3. Severe psychiatric or psychological disorders, such as major depressive disorder or schizophrenia. 4. Presence of ferromagnetic or other implants that may be affected by a magnetic field, such as deep brain stimulators, intracranial or intracardiac stents, cardiac pacemakers, artificial heart valves, or cochlear implants. 5. Pregnant or breastfeeding women, or individuals with a possibility of pregnancy. 6. Uncontrolled medical conditions such as arrhythmias, angina, transient ischemic attacks, vascular aneurysms or dissections, systemic infections or fever, or malignancies. 7. Conditions that may affect the collection or accuracy of study data, such as a history of drug or alcohol abuse within the past 12 months, current use of antipsychotic medications, sedative-hypnotics, or medications that affect dopamine metabolism (e.g., levodopa, pramipexole, rasagiline). 8. Prior exposure to transcranial magnetic stimulation (TMS) or other physical therapies within the past 3 months. 9. Participation in any other clinical trial currently or within the past 6 months. 10. Inability to comply with the treatment and assessment requirements of the clinical trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Scale for Assessment and Rating of Ataxia (SARA);Unified-Parkinson Disease Rating Scale PART 3 (UPDRS-III); | — |
Secondary
| Measure | Time frame |
|---|---|
| Unified Multiple System Atrophy Rating Scale (UMSARS);Montreal Cognitive Assessment (MoCA);EuroQol-5 Dimensions (EQ-5D);Brain-Derived Neurotrophic Factor (BDNF);Near-infrared imaging indicators;Ruidong Quantitative Motor Function Assessment System;Eye know Eye Tracker indicators;Functional magnetic resonance indicators; | — |
Countries
China
Contacts
Public ContactHong Jiang
The Third Xiangya Hospital of Central South University
Outcome results
None listed